EC 620-176-8
Also known as JARDIANCE.
Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.
